To investigate the natural history, cause of death, and end-of-life experiences of individuals diagnosed with dementia with Lewy bodies (DLB). DESIGN: Twenty-question online survey administered through the Lewy Body Dementia Association. SETTING: United States. PARTICIPANTS: Caregivers, family, and friends of individuals who died in the past 5 years with a diagnosis of DLB (survey respondents: n = 658, 89% female, median age 50-69). MEASUREMENTS: The survey included 3 questions about the respondent's background and 17 about the end-of-life experiences of the person with DLB. Topics included time from symptom onset and diagnosis to death, cause of death, advance directive completion, end-of-life education, hospice use, and location of death. Results were analyzed descriptively. RESULTS: Most individuals with DLB died within 5 years of diagnosis (median 3-4 years). Respondents indicated that physicians rarely discussed what to expect at the end of life (40% total, but only 22% to a helpful degree) and that the caregiver usually initiated such conversations. Death was usually expected, but fewer than half of respondents felt prepared for what to expect. Seventy-eight percent used hospice, usually at home or in skilled care, with wide variations in duration. Failure to thrive was the most common cause of death (65%), followed by pneumonia and swallowing difficulties (23%), other medical conditions (19%), and complications from falling (10%) (multiple causes allowed). CONCLUSION: Study results highlight a critical need for better prognostic counseling and education for persons and families living with DLB. The results of the current study can inform such counseling, but additional studies are needed to further explore expected prognosis of individuals diagnosed clinically with DLB and optimal use of palliative care services. J Am Geriatr Soc 67: 67-73, 2019. Key words: dementia with Lewy bodies; Lewy body disease; cause of death; terminal care; hospice care L ittle is known about the natural history and end-of-life experiences of individuals with dementia with Lewy bodies (DLB). Studies of clinical cohorts suggest that persons with DLB survive a median of 3.2 years to 3.7 years after presentation 1,2 or 5.3 years after symptom onset.
L
ittle is known about the natural history and end-of-life experiences of individuals with dementia with Lewy bodies (DLB). Studies of clinical cohorts suggest that persons with DLB survive a median of 3.2 years to 3.7 years after presentation 1,2 or 5.3 years after symptom onset. 1 Pathology series report 6.5 years to 8.3 years between symptom onset and death. [3] [4] [5] Cause of death is largely undescribed. In a study of individuals with Lewy body dementia, dementia was a contributor to death 71% of the time; circulatory and respiratory causes contributed 45% and 38%, respectively. 6 These findings provide little practical assistance for counseling individuals with DLB and their families. Only 35% of dementia caregivers say that they received advice about what to expect. 7 Knowledge from other diseases is little help for counseling individuals with DLB, who have shorter survival and die at a younger age than those with Alzheimer's disease (AD). 2, 3 Expected cause of death is also different; individuals with Lewy body dementia have more than double the likelihood of respiratory death as those with AD. 6 Disease duration is also shorter for individuals with DLB compared to Parkinson's disease (PD). Individuals with PD have a median survival of 9.1 years after diagnosis and more than 25% of individuals with PD live 20 years after diagnosis. Causes of death in individuals with PD are similar to those in individuals without PD, 10 in contrast to DLB. 6 Improving end-of-life care is a top dementia research priority. 11 There is increasing interest in the role of palliative care in dementia (including hospice), 12 but most individuals with dementia do not access palliative care services. 13 When palliative care is used in dementia, it is commonly initiated only in the last weeks of life, 13 possibly because recognizing the end of life in dementia can be challenging. 14 It is likely that such uncertainty hinders care of individuals with Lewy body dementia, more than half of whom specialists refer back to their primary care physicians for ongoing care. 15 The current study aimed to investigate cause of death and experiences of individuals with DLB and their families at the end of life.
METHODS
A survey was administered to caregivers, family members, and friends of individuals who died with a DLB diagnosis. The principal investigator (MJA) developed the survey, which was revised in response to suggestions from Lewy Body Dementia Association (LBDA) staff, 2 experts guiding the LBDA, and 3 caregivers of individuals who died from Lewy body dementia. Collaborators pilot-tested the online-only RedCap survey before production. The survey included 3 questions about respondent background and 17 about end-of-life experiences (Supplementary  Table S1 ). Item responses were optional once eligibility was established. Given confusion surrounding Lewy body dementia terminology, the survey included a question asking the respondent to indicate the timing of dementia onset in relationship to any parkinsonism so as to identify a cohort more certain to represent DLB. Respondents were allowed to indicate more than 1 reason for cause of death. Study approval was obtained from the University of Florida institutional review board (IRB201701657).
Subjects were recruited through the LBDA using a website banner ad, a website study landing page, social media postings, and emails to individuals subscribed to the LBDA's mailing list. Individuals were invited to participate if they could complete an online English-language survey and were a caregiver, family member, or friend of an individual who had died with a diagnosis of DLB in the past 5 years.
Survey results were analyzed using a spread sheet (Excel, Microsoft Corporation, Redmond, WA). Data were assessed using descriptive statistics. Data for 2 cohorts were analyzed: the full responding cohort and the cohort for which a DLB diagnosis was more certain.
RESULTS

Respondent Characteristics
Six hundred thirty-six individuals completed the survey, and 22 responded to enough questions to contribute to some analyses (maximum N = 658). An additional 71 individuals did not proceed past informed consent; 19 indicated that their loved one died before 2012 and the survey terminated, and 50 stopped after responding to 1 or 2 fields. Eighty-one percent (529) indicated that the dementia was before or concurrent with parkinsonism, 80 (12%) indicated that PD was diagnosed first, and 36 (7%) indicated uncertainty. Respondents were mostly women aged 50 to 79 and were more commonly children than spouses or partners ( Table 1 ). Other relationships in the full cohort included siblings (13, 2%), grandchildren (4, 0.6%), other family (11, 2%), friends (2, 0.3%), and other (8, 1%). Responses were largely similar when compared according to sex and role (Supplementary Table S2 ).
Natural History
Seventy-six percent of the total cohort (472/618) died within 5 years of diagnosis, including 12% (77/618) who died in the first year ( Figure 1A , median 3-4 years). Median time between symptom onset and death was 5 to 6 years, but 12% of both cohorts had had symptoms for longer than 10 years ( Figure 1B ).
Advance Care Planning
Forty-seven percent of the total cohort (303/643) reported early (in the first 1-2 years) advance care planning (ACP) with their physician, and 46% (296/642) reported early ACP with others, most commonly attorneys (205/296, 69%), but also nurses (70/296, 24%), social workers (68/296, 23%), and others (62/296, 21%). When such early conversations Advance directives were in place before DLB diagnosis 70% of the time (446/635). Only 10% of each cohort with an advance directive in place at diagnosis indicated a subsequent change based on the DLB diagnosis. Twenty-two percent (139/628) in the full cohort indicated that their physician discussed what to expect at the end of life; another 18% (n=111) said that their physician discussed what to expect but not to a helpful degree. Responses were similar in the DLB cohort (123/510, 24% discussed what to expect; 90/510, 18% not helpful). The family or caregiver usually initiated the discussion (123/248, 50%), followed by the physician (73/248, 29%), and person with DLB (20/248, 8%). Seventy-four percent of the full (460/625) and 72% of the DLB (366/506) cohort described death as expected, but less fewer than half of respondents felt prepared for what to expect (full cohort: 298/625, 48%; DLB cohort: 244/506, 48%). Respondents reported that physicians discussed hospice or palliative care approximately 60% of the time (full cohort: 384/625, 61%; DLB cohort: 322/507, 64%). Other resources described as helping respondents prepare included hospice or palliative care staff (415/659, 63%), print or online educational resources (273, 41%), specialized physicians (195, 30%), nursing home staff (143, 22%), primary care physicians (121, 18%), support groups (109, 17%), and social workers (84, 13%).
Of the 644 individuals responding to questions regarding brain autopsy or donation discussions, 371 (58%) reported no conversation, 107 (17%) said autopsy and brain donation were discussed but not pursued, 45 (7%) proceeded with brain donation, and 52 (8%) proceeded with autopsy (69 responded "other").
Circumstances of death
In the total cohort, 282 of 650 (43%) individuals died in skilled nursing or memory care, 231 (36%) died at home, 57 (9%) died at a hospice facility, and 55 (8%) died in the hospital (25 "other"). Responses were similar in the DLB cohort. Almost 80% reported using hospice services (total cohort: 489/624, 78%; DLB cohort: 394/504, 78%). Hospice duration varied widely (Figure 2 ; median 1-2 months). Most respondents felt hospice was started at the right time (full cohort: 321/488, 66%; DLB cohort: 267/394, 68%). A substantial minority indicated hospice was started too late (full cohort: 121/488, 25%; DLB cohort: 92/394, 23%), often when hospice was initiated within weeks of death (<1 week: 31/121 (26%); 1-2 weeks: 19/121 (16%); 2-4 weeks: 26/121 (21%); 1-2 months: 14/121 (12%); 2-3 months: 9/121 (7%); 4-6 months: 13/121 (11%); 6-12 months: 5/121 (4%); >12 months: 3/121 (2%); Most respondents reported a single cause of death (86% of both cohorts). Stopping eating and drinking (failure to thrive, sometimes also called "the dwindles" or "inanition") was the most commonly reported cause of death (Table 2) . If including those respondents who indicated DLB or Lewy body dementia as the only cause of death, the frequency of death related to dementia or failure to thrive reached 70%. Complications from pneumonia or trouble swallowing was the second most common cause of death. Other infections were the most commonly contributing medical condition, usually urinary tract infection or sepsis. Deaths related to antipsychotic administration and suicide were uncommon but were reported in write-in responses. Three respondents indicated that the individual with DLB died after administration of haloperidol, 4 described reactions after unspecified antipsychotics, and 1 described seizures after quetiapine initiation. Nine respondents reported contributions from medications such as anesthesia or morphine.
DISCUSSION
Most caregivers and family members responding to the survey were women, consistent with a U.S. population-based study finding that DLB was diagnosed more commonly in men. 16 Although the survey was not restricted to caregivers, respondent demographic characteristics were similar to those reported for dementia caregivers in the United States, with 34% aged 65 and older and more than half being offspring. 17 The proportion of female respondents was higher than the proportion of female U.S. dementia caregivers (two-thirds), possibly reflecting the fact that women were more likely to care for someone with cognitive, functional, and behavior problems (as seen in DLB) and to indicate a need for support groups (and thus more likely to connect with the LBDA). 17 This survey found that most individuals diagnosed clinically with DLB died within 5 years of diagnosis. Fewer than half of respondents reported ACP with physicians early in the disease, although 70% reported completing advance directives before diagnosis. Individuals with DLB were able to participate actively in these conversations most of the time. Respondents indicated that physicians rarely discussed what to expect at the end of life (40% total, only 22% to a helpful degree), and the caregiver usually initiated conversations. Death was usually expected, but fewer than half of respondents felt prepared for what to expect. Seventy-eight percent used hospice, usually at home or in a skilled care facility, with wide variations in duration. Most respondents felt that hospice was initiated at the right time, but 25% felt it was started too late. Failure to thrive was the most common cause of death, followed by pneumonia, other medical conditions, and complications from falling.
Median disease duration from diagnosis to death in this series was 3 to 4 years, matching smaller clinical cohorts reporting 3.2-1 and 3.7-year 2 disease durations. Median duration from symptom onset to death was 5 to 6 years, similar to a clinical series reporting a median 5.3-year duration between symptom onset and death. 1 This suggests that there has been little change in disease duration since 2000. 1 These clinical results are in contrast to pathology series, in which reported average disease durations were 7.3 years, 3 8.3 AE 3.8 years (for patients with diffuse Lewy body disease), 4 and 6.5 years for individuals with non-rapidly progressive disease (range 2-10 years; rapidly progressive: mean duration 9 months, range 3-15 months). 5 Ascertainment methods are the most likely reason for these differences. The current cohort comprised individuals diagnosed with DLB clinically as reported by family members, in contrast to pathologically confirmed cases from individuals enrolled in longitudinal studies at tertiary care centers. Although pathology remains the criterion standard for DLB diagnosis, understanding expected disease duration for clinically diagnosed individuals is critical. In the absence of biomarkers, clinical diagnoses inform prognosis and counseling. The discrepancy between timing of symptom onset and diagnosis is not surprising; individuals with DLB often see multiple physicians over several years before receiving the correct diagnosis. 15 Respondents reported high rates of completed advance directives. The frequency of ACP in individuals with DLB is not established, but a 2008 study found that 71% of participants with mild cognitive impairment or early AD and 70% of participants with moderate to severe AD reported engagement in ACP, 18 consistent with our findings. ACP is part of dementia management quality measures 19 and proactive ACP allowing active involvement of the individual is important for optimal dementia care. 20 ACP can also improve the quality of dying of nursing home residents with dementia. 21 The lack of physician discussions regarding what to expect at the end of life in DLB is troubling. Dementia quality measures recommend "comprehensive counseling regarding ongoing palliation and symptom management and end of life decisions within 2 years of initial diagnosis or assumption of care," 19 but only 22% of respondents reported a helpful conversation with a physician regarding what to expect at the end of life with DLB, and fewer than half of respondents felt prepared. It is likely that reasons for this are multifactorial, including lack of published data, sufficient experience with DLB on which to base counseling, time, and resources. Caregivers of individuals with Lewy body dementia, 22 dementia in general, 7 and dementia at the end of life 23 and individuals with early-onset dementia and their caregivers 24 describe better understanding of the disease and what to expect as unmet needs. In one study, more than one-quarter of families reported not knowing that dementia could lead to death, and awareness of dementia as a terminal condition was associated with greater comfort at the end of life. 25 Use of hospice for individuals with DLB was higher than reported rates of dementia palliative care. 13 This is important given evidence that hospice improves quality of care of individuals dying with dementia, 26 although research is limited. 27 More than 40% of individuals had hospice initiated less than 1 month before death, limiting potential benefits and suggesting a need for better physician recognition of end-of-life symptoms in individuals with dementia. Prognostication and timely recognition of dying is one of 11 domains of optimal dementia palliative care. 20 Symptoms such as confusion, urinary incontinence, pain, low mood, dyspnea, and loss of appetite are common endof-life symptoms in individuals with dementia. [28] [29] [30] Although only 8% of individuals died in the hospital, burdensome interventions such as hospitalization are common in the last 3 months of life of individuals with advanced dementia 28 and are an area for continued improvement. One important study finding is that most individuals with DLB died from complications directly related to the dementia diagnosis, most commonly stopping eating and drinking (failure to thrive) or aspiration and pneumonia. That individuals with advanced dementia can die from failure to thrive, pneumonia, and other infections is not surprising, 28 but the degree to which this occurs in DLB has not been described previously and is of critical importance when counseling individuals with DLB and their families regarding prognosis, expectations, and end-of-life decisionmaking (e.g., relating to living situation, hospice initiation). It also emphasizes the importance of early discussions of preferences regarding enteral nutrition through percutaneous endoscopic gastrostomy tubes, which are generally discouraged in advanced dementia because they do not extend life or improve its quality. 31 Eight individuals died after antipsychotic medication administration. Sensitivity to antipsychotic medications was previously a suggestive feature in DLB diagnostic criteria 32 based on research showing that 81% of individuals with DLB receiving antipsychotics had adverse reactions, half of which were severe. 33 In the most recent criteria, antipsychotic sensitivity was changed to a supportive feature based on reduced antipsychotic prescribing in DLB. 34 Our results suggest that, although uncommon, reactions to antipsychotic medications remain a contributor to morbidity and mortality. There may be times when antipsychotic use is warranted based on risk-benefit assessments and limited options, 35 but antipsychotic administration is a potentially modifiable cause of death in DLB.
Suicide was the reported cause of death in 5 responses. Although suicide in the context of DLB gained national attention with the death of actor Robin Williams in 2014, no prior work has described suicide frequency in individuals with DLB. Suicide in individuals with dementia is rare, but risk factors include depression and other psychiatric comorbidities, prior suicide attempts or self-harm, a recent dementia diagnosis, and young age. 36 Individuals with DLB may be at higher risk than those with AD given greater preserved awareness of cognitive-behavioral symptoms 37 and cognitive fluctuations leading to oscillating and sometimes unpredictable emotions. Screening for depression and other behavioral and psychiatric symptoms is important in dementia care 19 and current findings emphasize the need to ask about risk factors and suicidal ideation.
Study limitations include reliance on respondent report of a diagnosis of DLB without evidence of physician confirmation. Inclusion criteria required the individuals with DLB to have died in the preceding 5 years to understand current practices and limit recall bias, but inaccurate recall is a risk of any retrospective survey. Recruitment through the LBDA could have resulted in a highly engaged respondent population, but the large sample size suggests that results have at least fair generalizability. It is also possible that certain individuals, such as those with more psychological distress, were more likely to respond to the survey and that those views are thus overrepresented. Respondent location was not queried, but the LBDA is U.S.-based, so responses may largely reflect U.S. health system experiences. The absence of racial and ethnic data also limits assessment of generalizability. The survey was anonymous, and it is possible that individuals completed the survey more than once or that multiple respondents described experiences relating to a single individual with DLB. More than half of respondents were offspring, some of whom may not have attended clinical visits, but the percentage of "I don't know" responses was less than 8% for each question. Finally, the survey focused on respondents' experiences and perceptions of care and may not reflect what actually occurred or appropriate timing according to others.
Study results highlight a critical need for better prognostic counseling and education for persons and families with DLB. These survey results can inform such counseling, but natural history studies are needed to explore prognosis further. Research is also needed to understand predictors of approaching end of life in individuals with DLB to better inform patient and family counseling and timing of hospice initiation. Finally, more research is needed to understand the experiences of persons with DLB and their families at the end of life to identify opportunities for improved care.
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